title: [Monoclonal antibodies in dermatological practice].
abstract: The recent approval of several monoclonal antibodies in dermatological treatment in recent years appears to be only only the phase in development of monoclonal antibody therapy for skin diseases. Several analyses point to the growth of the market for these drugs, and forecast an even higher expansion of the use of monoclonal antibodies in dermatologic therapy. The possible application of several monoclonal antibodies, including, adalimumab, efalizumab, infliximab, rituximab, in skin diseases is discussed.
authors.affiliation: CSK MSWiA w Warszawie, Klinika Dermatologii. irudnicka@cskmswia.pl
authors.forename: Lidia
authors.initials: L
authors.lastname: Rudnicka
authors.forename: Elzbieta
authors.initials: E
authors.lastname: Szymańska
authors.forename: Elzbieta
authors.initials: E
authors.lastname: Oledzka
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Olszewska
mesh_terms: D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D010392:Pemphigus / Q000188:drug therapy*; D011565:Psoriasis / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000069283:Rituximab; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept; C472181:efalizumab